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Abstract. Transition from malignant schwannoma to malignant
triton tumor is analyzed in a case report on a patient with
recurring cancers and suspected familial predisposition. It is
hypothesized that rhabdomyoblastic differentiation, which
distinguishes triton from schwannoma, might be attributable
to Hedgehog-Patched pathway malfunctioning. Loss of one
Patched gene allele was found in the tissue of advanced triton,
but the retained allele had no exon or promoter mutations.
Protein levels at early cancer stages indicated possible Patched
response to the pathway activation in the first occurrence of
triton tumor. Later, in the recurring triton, Patched expression
was several times lower than in the control tissue, suggesting
that haploinsufficiency was aided by silencing of the remaining
allele, although its promoter was not hypermethylated. These
findings may justify further investigation of the Hedgehog-
Patched pathway role in triton malignancies, especially because
of the recent research on the therapeutical potential of the
pathway.
Introduction
Malignant triton tumor (MTT) is a very rare variant of malig-
nant schwannoma with rhabdomyoblastic differentiation,
which carries a poor prognosis despite wide excision, chemo-
therapy, and radiotherapy. This aggressive tumor, arising in
the peripheral nerve sheath, is comprised of both malignant
schwannoma cells and malignant rhabdomyoblasts. Less than
one hundred cases were reported in the twentieth century (1),
after the first case described in 1932 (2). MTT predominantly
affects young patients, and is associated with neurofibromatosis
type 1 (NF1) in >50% cases (3). In addition, less than one
third of triton malignancies are located in the head and neck
region (4), so that the intracranial tumor of an elderly woman
with no symptoms of NF1, which is reported here, belongs to
a very small subset of MTT cases.
Schwann cells derive from the neural crest via Schwann
cell precursor, in myelating or non-myelating form (5).
Schwannomas are usually slowly growing tumors, derived
from Schwann cells, and surrounding the peripheral, cranial
or autonomic nerves. They occur at a wide variety of sites,
frequently within the head and neck region, and account for
about 8% of intracranial and 29% of spinal tumors (6).
Malignant schwannoma is a rare aggressive schwannoma
variant, with prognosis not much better than MTT. About
30% of malignant schwannoma cases occur sporadically of
unknown etiology, as the sole morbid finding. The remaining
70% are associated with NF1; their biological behaviour is
more aggressive than that of simple malignant schwannomas;
their course is rapid and the prognosis is dismal. Local recur-
rences are frequent, and distant metastases, preferentially
situated in the lung and brain, are present in about 50% of the
cases.
We report on a family with two members affected by
malignant schwannoma; in one patient schwannoma developed
into MTT, whereas the fate of the other patient is not known.
Our study was primarily directed towards genetic aspects
which could be relevant for development and progression of
the triton malignancy, focusing on the Hedgehog-Patched
signaling pathway. The pathway was selected because of its
known role in Schwann cells development, and because of its
implication in rhabdomyosarcoma. 
The Hedgehog-Patched signaling pathway is crucial for
the morphogenesis of nervous system. It is involved in neural
cell precursor proliferation and regulates neural stem cells in
various stages of development. Sporadic brain tumorigenesis
may be attributable to inappropriate activation or inactivation
of the pathway (7,8). The Hedgehog (Hh) family in mammals
consists of three members: Shh (Sonic Hedgehog), Dhh (Desert
Hedgehog) and Ihh (Indian Hedgehog). Dhh is secreted from
Schwann cells and regulates the formation of surrounding
tissues (5), but in general Shh is more frequently found to
be involved in normal and especially in aberrant activation
of the pathway. When any Hh ligand binds to the trans-
membrane receptor protein Patched (Ptc, in humans Ptch1),
the co-receptor Smoothened (Smo) is relieved from
repression by Ptc, which triggers signal transduction cascade
within the cell. At the downstream end of the pathway, the
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active form of Gli transcription factor is translocated to the
nucleus, and expression of the pathway target genes is
stimulated (Fig. 1), which leads to cell proliferation. Gli1,
Gli2 and Gli3 proteins exibit different functions in different
tissues, and are generally involved in patterning of the nervous
system and brain development. In particular, the active form
of Gli1 binds to PTC promoter and stimulates its expression,
so that new Ptc protein may limit and eventually terminate
the pathway activity. When this autoregulatory mechanism is
impaired, frequently by genetic or epigenetic alterations of
PTC, malformations or cancer may develop, which has been
particularly convincingly demonstrated on mouse models of
rhabdomyosarcoma (9).
In addition to the analysis of the pathway genes PTCH1,
SHH, SMO and GLI1, we also examined p16 as a potential
regulator of cell cycle progression and proliferation in
Schwann cells (10) and NF1 gene for its potential role in
schwannoma development (11). PCNA expression was
measured as a general indicator of cell proliferation.
Materials and methods
Subjects and samples. Blood and tissue samples from three
consecutive tumors (in liquid nitrogen and in paraffin block)
of one patient (SCH) were analyzed. Her sister (S3), diagnosed
with malignant schwannoma, was not available for analysis.
Blood samples were obtained from four unaffected relatives
S1, S2, S4, S5 (family tree in Fig. 2).
Patient's history. Female patient (SCH) had first symptoms
(swelling and pain in the inner corner of the right eye) in
1999, at the age of 68. After clinical exams (echography,
CT) and tumor removal, pathohistological diagnosis (PHD)
of malignant schwannoma was given. Several months later,
in the spring of 2000, a new tumor of the right orbit was
detected, exenteration of orbit was performed, and PHD was
triton malignum. The patient was irradiated, but at the end of
2000 lymphadenopathia was detected, and biopsy of lymph
node in submandibular area showed malignant cells; radical
neck dissection was done, and PHD was determined as
metastaticum lymphonodorum. FACS analysis showed
aneuploidy and high mitotic index, and patient's neck was
again irradiated. In mid 2001, the patient had overgrowth
of parotid gland, complete parotidectomy was done, and
PHD was triton malignum rec. At the beginning of 2002,
new tumor located preauriculary was resected (again triton
malignum rec). In the following months the patient had
serious loss of weight, bone scintigraphy showed metastatic
process, and she died in November, 2002. Table I lists tumor
samples that were available for analysis and the tests we
performed. 
DNA extraction and PCR. DNA samples were extracted from
blood leukocytes and from frozen tumor or paraffin tissues
by standard methods. DNA samples were typed for ten
short tandem repeat polymorphisms, D9S196, WI-19346,
GDB:583921, PTCH intra, ex 1 UTR, D9S287, D9S180,
D9S176, D9S1783 and D9S127, spanning chromosome
region 9q22.3-31 (12). Intragenic PTCH is located in the first
intron of PTCH1 between exons 1 and 2 (13). Polymorphic
marker ex 1 UTR is located upstream of exon 1 (14). All
other primer sequences for polymorphic markers were taken
from online NCBI database (www.ncbi.nlm.nih.gov).
PCR reaction was performed in 25 μl reaction mixture
using Multiplex PCR kit (Qiagen) containing 200-300 ng of
template DNA and 8 to 20 pmol/l of each primer pair. PCR
system (GeneAmp PCR system 2400, Applied Biosystems)
was set for 19-25 cycles (15). 
For LOH analysis fluorescent forward primers were used.
Multiplex PCR products (1 μl) was mixed with 12.5 μl of
HiDi formamide (Applied Biosystems) and 0.5 μl GeneScan
500 LIZ size standard (Applied Biosystems), and loaded on
ABI PRISM 310 automatic sequencer (Applied Biosystems).
The analysis was made using Gene Mapper v3.0.
For three markers in 9p21 (IFNA, D9S126 and D9S104),
PCR reaction was performed in 25 μl reaction mixture
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Figure 1. Shematic presentation of the main members of the Hh-Ptc signaling pathway.
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containing 100 ng of template DNA, 200 μmol/l deoxy-
nucleoside triphosphate (dNTP), 1.5 mmol/l MgCl2, 10 pmol/l
each primer, 1.25 U Taq polymerase (AmpliTag Gold® DNA
polymerase, Applied Biosystems) in 10 mmol/l Tris-HCl
buffer. PCR system (GeneAmp PCR system 2400, Applied
Biosystems) was set for 25-35 cycles, with the parameters
published previously (16). LOH analysis was performed on
8-12% polyacrylamide gel, as described previously (17).
LOH analysis of NF1 locus was performed by RFLP (18).
Mutation analysis. All 23 exons of PTCH1 gene (www.ncbi.
nlm.nih.gov) were PCR amplified, subjected to additional 10
min 95˚C denaturating step, followed by 30-min reannealing,
and then loaded on the dHPLC (denaturing high-performance
liquid chromatography) WAVE DNA Fragment Analysis
System (Transgenomic, Omaha, NE, USA). Twenty-three
exons of PTCH1 and 3 exons of p16 gene were sequenced
in both directions using the Big Dye Terminator v.1.1 Cycle
Sequencing kit and analyzed on ABI PRISM 310 Genetic
Analyser using DNA sequencing Analysis Software version
5.1. (Applied Biosystems).
Real-time PCR (RT-PCR). Total cellular RNA was isolated
from tissue samples of triton (PHD3) and healthy neural tissue
(Nervus auricularis magnus, nerve from plexus cervicalis, the
closest in origin to normal tissue). 
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Figure 2. Linkage analysis was performed with ten polymorphic markers for the 9q22.3-31 region. SCH is the patient with MTT, S3 is her sister diagnosed
with malignant schwannoma, other relatives are unaffected.
Table I. Tumor samples and tests performed.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Sample label and date Tumor diagnosis Tests performed
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
PHD1, September 1999 Malignant schwannoma Immunohistochemistry
PHD2, March 2000 Triton malignum Immunohistochemistry 
PHD3, January 2002 Triton malignum rec LOH analysis, PTCH1 exon sequencing and promoter 
methylation, RFLP, RT-PCR expression analysis
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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The isolation was performed in two steps: first, tissue was
homogenized in TRIzol reagent (Invitrogen), RNA was
extracted, washed with 75% ethanol and dissolved in water
and, as a second step, run through High Pure RNA Isolation
Kit columns (Roche), and finally dissolved in 30 μl elution
buffer. Complementary DNA (cDNA) was synthesized from
each of the samples starting from 1 μg of total RNA, using
TaqMan reverse transcription kit (Applied Biosystems). 
Real-time PCR analysis was performed on Chromo4
Real-time PCR system (Bio-Rad), in total volume of 10 μl,
using iQ SYBR Green supermix (Bio-Rad). Expression of
5 different genes was analyzed, with Arp (acidic ribosomal
protein) as a reference housekeeping gene (19). All samples
were done in triplicates, and blanks were included. Primers
used for real-time PCR amplification were published
previously (20). Real-time PCR program was: 95˚C for 3 min,
and 45 cycles of 95˚C for 15 sec and 61˚C for 1 min,
followed by plate read step. Product specificity was deter-
mined by melting curve analysis and on a 2% agarose gel
stained with ethidium bromide. Data were analyzed using the
2-ΔΔCt (relative quantitation) method, after ensuring that all
primer sets amplified their respective sequence targets with
similar efficiencies.
Immunohistochemistry. Tumor paraffin sections were de-
paraffinated, then incubated at 95-99˚C for 40 min in Epitope
Retrieval Solution (Dako) and cooled to room temperature.
Endogenous peroxidase was blocked with methanol-hydrogen
peroxide solution (10 ml 30% H2O2 in 90 ml methanol) for
10 min, and Protein-block Serum-Free (Dako) was applied
for 10 min. Primary rabbit anti-Ptch1 antibody (dilution
1:500) (gift from Allen Bale), Gli1 (ab7523, abcam), or Hh
(sc-9024, Santa Cruz, reacts with all 3 Hh proteins) was
incubated overnight at 4˚C. After 1-h incubation with universal
secondary antibody (anti-goat, -mouse, -rabbit; Dako), the
sections were incubated with PAP (rabbit, Dako) for 1 h,
then with DAB (Dako) for 7 min, and counterstained with
hematoxylin. As negative controls, the sections were processed
in the same way but without the primary antibody. 
Results
Typing with polymorphic markers. Typing with ten markers
for the 9q22.3-31 region revealed a large deletion of about
10 Mb in PHD3 tumor tissue (Table II), indicating loss of
one entire allele in PTCH1 region. Haplotype analysis with
the same markers (Fig. 2) was not particularly informative
because the affected sister was not among the available
relatives; the patient's (SCH) haplotype for two markers
(D9S176, D9S1783) is not replicated among the healthy
family members.
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Table II. Typing with polymorphic markers for 9p21 and
9q22-31.a
––––––––––––––––––––––––––––––––––––––––––––––––– 
Polymorphic marker SCH blood SCH tumor
––––––––––––––––––––––––––––––––––––––––––––––––– 
IFNA 1,2 1,2
D9S126 1,1 1,1
D9S104 1,2 1,2
D9S196 2,2 2,LOH
WI-19346 1,3 1,LOH
GDB:583921 1,2 1,LOH
PTCH intra 1,2 1,LOH
ex 1 UTR 1,2 LOH,2
D9S287 2,5 2,LOH
D9S180 1,5 1,LOH
D9S176 2,4 2,LOH
D9S1783 2,3 LOH,3
D9S127 4,4 4,LOH
––––––––––––––––––––––––––––––––––––––––––––––––– 
aAllelic fragments are numbered from the smallest to the highest.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. RT-PCR expression levels of PTCH1, SMO, SHH, GLI1 and
PCNA (relative to ARP housekeeping gene) in PHD3 tumor (white columns)
and in the control tissue (black columns).
Table III. Immunohistochemical analysis in early cancer
stages.
––––––––––––––––––––––––––––––––––––––––––––––––– 
SCH tumor Antibody Immunohistochemical
tissue activity
––––––––––––––––––––––––––––––––––––––––––––––––– 
PHD1 Ptch1 Negative
Gli1 Negative
Hh Mildly positive
PHD2 Ptch1 Positive
Gli1 Negative
Hh Negative
––––––––––––––––––––––––––––––––––––––––––––––––– 
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None of three markers for the p16 region on 9p21 showed
allelic loss (Table II); one marker was homozygous (D9S126).
RFLP analysis of NF1 exon 5 did not show allelic loss (data
not shown).
Mutation and methylation analysis. Neither dHPLC analysis
nor subsequent sequencing of all PTCH1 exons revealed
any mutations in the PHD3 tumor tissue (data not shown).
Methylation analysis of PTCH1 promoter (20) did not show
hypermethylation nor any mutations in the promoter sequence
(data not shown). No mutations were detected in exon
sequences of p16 gene (data not shown).
RT-PCR expression analysis. Expression levels of PTCH1,
SHH and GLI1 in the PHD3 tumor tissue were by far lower
than in the control sample. SMO was at the same level in
both samples, while PCNA was slightly higher in the tumor
(Fig. 3).
Protein expression in PHD1 and PHD2 tumors. Immuno-
histochemical analysis of Ptch1, Hh and Gli1 activity in
early stages of malignancy showed significant increase of
Ptch1 protein level in the consecutive tumors (Table III
and Fig. 4). PTCH1 seems to have been activated in PHD2
without detectable Hh signal (although possibly a mild signal
had appeared in PHD1).
Discussion
MTT contains a substantial proportion of mature rhabdomyo-
blasts, but the tumor is derived from and behaves more like
malignant schwannoma than rhabdomyosarcoma (4). Its
molecular genetic basis is not known, which is not surprising
because pathogenesis of schwannoma itself is not clear. Most
schwannomas are associated with neurofibromatoses, and
different genes are implicated in the syndrome sub-types:
NF1 and NF2 genes were found altered in the respective
tumors, and a new tumor suppressor gene is being investigated
in schwannomatosis (which has recently been recognized
as a nerofibromatosis distinct from the type 2). Malignant
schwannomas appear to be mostly associated with NF1, but
their low incidence in the syndrome and high proportion of
sporadic cases do not suggest decisive role of NF1 gene in
this malignancy.
In our family with two schwannoma cases, no association
with neurofibromatoses was apparent, nor did RFLP analysis
of NF1 gene in the MTT tissue indicate its involvement in the
tumor. Regardless of the limited knowledge on schwannoma
genesis, it can reasonably be supposed that rather complex
genetic alterations are required for MTT development due to its
extremely low incidence, and that some of these alterations are
not typically involved in malignant schwannoma progression.
For reasons outlined in the introduction, Hedgehog-Patched
pathway malfunctioning seems to be a likely candidate for the
MTT-specific alterations which convert malignant schwanoma
into triton.
The large deletion we found on one Patched allele in
PHD3 tumor clearly supports this hypothesis. Although mere
haploinsufficiency of the PTCH1 gene, even at the
constitutional level, causes usually mild dissorders known as
Gorlin syndrome (NBCCS or BCNS), it has also been
observed that the gene may retain one wild-type alelle in
some tumors for which the syndrome predisposes. In
particular, recent analysis of rhabdomyosarcoma on mouse
models (9) showed that wild-type allele could be silenced by
the promoter methylation, while the mutated PTC allele
overexpressed non-functional protein.
However, we did not find increased PTCH1 promoter
methylation in the PHD3 triton sample analysis (using the
same procedure which gave positive results for some other
neoplasia analyzed in our laboratory (20). Gli1 binding site
was not methylated, and there were no mutations in the
promoter sequence. This result does not help explain very low
expression of PTCH1 observed in our PHD3 sample of MTT,
which is so far below the control tissue level that it can
hardly be attributed to haploinsufficiency alone. It is more
likely that some PTCH1 silencing mechanism was also
involved, and even non-homogeneous or reversible promoter
methylation (undetectable in our sample) cannot be ruled out.
The increased Patched expression in PHD2 sample, in
comparison to PHD1, suggests the pathway activation at the
onset of MTT transition from the former schwannoma. The
PTCH1 autoregulatory response may have been inadequate
due to the haploinsufficiency (although still visible during
PHD2), but subsequent involvement of a silencing mechanism
would better fit the expression profiles of PHD3.
Another explanation might be an alternative splicing of
Ptch1 protein into a truncated form with a dominant negative
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Figure 4. Immunohistochemical detection of Ptch1 (a), negative control (b), H&E staining (c). Olympus camera 40-10;  magnification x400.
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phenotype. It has been shown that this isoform is normally
present in brain and heart tissue, and it has been implicated
in medulloblastoma formation. This truncated protein can
abolish the activity of full-length protein, thus disrupting the
pathway (21).
Apart from the PTCH1 deletion, no genetic changes were
detected in the remaining assays. In particular, LOH analysis
of the 9p21 region and direct sequencing of p16 exons
indicated no alterations in this gene that could contribute
to the MTT proliferation. Also, haplotype investigation with
PTCH1 region polymorphic markers, which was undertaken
for four relatives of the affected family member, did not
reveal anything outstanding about her haplotype.
Therefore, our results indicate only the involvement of
Hedgehog-Patched pathway malfunctioning in MTT develop-
ment. One Patched allele is deleted, the other is not mutated
but its expression varies through different phases of tumor
progression. In PHD3, expression of PTCH1, SHH and GLI1
is far lower than in the control neural tissue; only SMO, the
gene that actually triggers the signal transduction to the
nucleus, parallels the control level. It should be noted, though,
that Hedgehog-Patched pathway malfunctioning is unlikely
to be involved in the genesis of the primary cancer, i.e. the
malignant schwannoma PHD1. In addition to previous argu-
ments, restriction of the pathway role to MTT progression is
also suported by the fact that malignant schwannomas have
not been reported as a Gorlin syndrome feature (which is
easily explained by very low incidence of the two conditions
- provided that they do not share any underlying genetic
causes).
Although a more reliable conclusion on the Hedgehog-
Patched pathway involvement in MTT cannot be made before
further cases are analyzed, the very possibility is worth
considering due to the recent advances towards therapeutical
exploitation of this pathway. 
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